Premium
Acceleration of Drug Development: A Collaboration of Many Stakeholders
Author(s) -
Reynolds K S
Publication year - 2013
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2013.63
Subject(s) - drug , drug development , clinical pharmacology , intensive care medicine , investment (military) , medicine , pharmacology , phase (matter) , business , risk analysis (engineering) , political science , chemistry , law , organic chemistry , politics
Modern drugs are used to treat and prevent diseases that previously led to morbidity and mortality. There is a high cost to this achievement—investment for each successful drug can exceed $1.8 billion. Late‐phase drug candidate failure decreases efficiency of drug development because each failure represents lost or delayed opportunity to develop successful drugs. Collaboration of stakeholders and the use of new science and knowledge management can reduce late‐phase failure and accelerate drug development. Clinical Pharmacology & Therapeutics (2013); 93 6, 455–459. doi: 10.1038/clpt.2013.63